ACXP Acurx Pharmaceuticals, Inc.
USHealthcareAs of 2026-08-24
Why ACXP matters now
Acurx Pharmaceuticals, Inc. (ACXP) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.40 with -4.76% on the session and $6.0M in market capitalization; recent performance reads 1-month -18.09% and YTD -38.15%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-1.7M, and EPS of $-1.12. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -251.7%.
The latest indexable market news headline is "Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Shawah Robert G. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.33
P/S
0.00
EV/EBITDA
0.91
DCF Value
$5,040.79
FCF Yield
-251.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-153.9%
ROA
-78.6%
ROIC
-108.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-1.7M | $-1.12 |
| Q4 2025 | $0.00 | $-1.6M | $-0.67 |
| FY 2025 | $0.00 | $-8.0M | $-5.32 |
| Q3 2025 | $0.00 | $-2.0M | $-1.23 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-2.09
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.